Paediatric Endocrinology and Diabetes Unit, Gafar Ibn Auf Specialized Children Hospital, Khartoum, Sudan.
Department of Paediatric Endocrinology and Diabetes, Gertrude Garden Children Hospital, Nairobi, Kenya.
J Pediatr Endocrinol Metab. 2020 Jul 28;33(7):879-884. doi: 10.1515/jpem-2020-0092.
Background Little has been published about hyperthyroidism in children from Sudan or Africa. In limited resource countries, lack of facilities and sociocultural factors might make international diagnosis and management guidelines difficult to follow. We aimed to determine the magnitude of autoimmune hyperthyroidism, clinical presentation, diagnosis, management and its outcome in Sudan. Method Records of all patients diagnosed as Graves' disease (GD) or Hashitoxicosis (HTx) were reviewed and missing data filled by interviewing patients and/or their families. Data including age, sex, clinical presentation, investigations, management and outcome were obtained. Results Eighty-eight patients, 80 with GD (F:M = 4.7:1) and 8 with HTx (F:M = 7:1), were diagnosed at 11.8 ± 3.05 and 11.23 ± 2.78 years, respectively (p = 0.52). GD patients were diagnosed based on presence of exophthalmos (66.25%), positive thyroid receptor autoantibodies (12.5%), prolonged illness duration (8.75%) or remission failure to only B blocker (16.25%). All GD patients were started on carbimazole and cumulative remission rate was 11.8%, 32.4% and 41.2% by end of the second, third and fourth year respectively, however it plateaus after that. While 12 GD patients underwent surgery, only three opted for radioiodine ablation. Conclusion Hyperthyroidism is not an uncommon problem. In absence of laboratory facilities, differentiation between GD and HTx can be made based on clinical grounds. Continuation of medical treatment for 4 years can increase the remission rate to 41.2%. In Sudan, surgery is the preferred method of definitive therapy.
关于苏丹或非洲儿童的甲状腺功能亢进症,相关文献报道较少。在资源有限的国家,由于缺乏设施和社会文化因素,可能难以遵循国际诊断和管理指南。我们旨在确定苏丹自身免疫性甲状腺功能亢进症的发病情况、临床表现、诊断、治疗及其结局。
对所有诊断为格雷夫斯病(GD)或毒性弥漫性甲状腺肿(HTx)的患者的记录进行了回顾,并通过访谈患者及其家属来补充缺失的数据。收集的资料包括年龄、性别、临床表现、检查、治疗及其结局。
共诊断出 88 例患者,其中 80 例为 GD(女:男=4.7:1),8 例为 HTx(女:男=7:1),年龄分别为(11.8±3.05)岁和(11.23±2.78)岁(p=0.52)。GD 患者的诊断依据为突眼(66.25%)、甲状腺受体自身抗体阳性(12.5%)、疾病持续时间较长(8.75%)或仅用β受体阻滞剂治疗失败后缓解(16.25%)。所有 GD 患者均开始使用甲巯咪唑,第 2、3、4 年末的累积缓解率分别为 11.8%、32.4%和 41.2%,但此后趋于稳定。12 例 GD 患者接受了手术,仅有 3 例选择了放射性碘消融治疗。
甲状腺功能亢进症并不少见。在缺乏实验室设施的情况下,可根据临床情况区分 GD 和 HTx。继续药物治疗 4 年可将缓解率提高至 41.2%。在苏丹,手术是确定性治疗的首选方法。